Alumis Inc. (ALMS)
| Market Cap | 673.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -98.11M |
| Shares Out | 56.37M |
| EPS (ttm) | -1.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 280,953 |
| Open | 12.50 |
| Previous Close | 12.54 |
| Day's Range | 11.75 - 12.63 |
| 52-Week Range | 11.75 - 13.53 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ALMS
Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we ... [Read more]
News
Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering
On Friday, Alumis Inc ALMS priced its initial public offering at $16/share, the low end of the range of $16 to $18, raising $210 million via 13.13 million shares offering.
Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut
Shares of biopharmaceutical firm Alumis opened nearly 16% below their initial public offering (IPO) price in their debut on the Nasdaq on Friday.
Therapy developer Alumis prices U.S. IPO at about $902 mln valuation
Alumis set the pricing of its U.S. initial public offering at $16 per share, the lower end of its price range, valuing it at around $902 million.
Alumis Announces Pricing of Initial Public Offering
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering
Therapy developer Alumis seeks up to $1 bln valuation in US IPO
Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday.
Alumis eyes $300 million in proceeds in IPO
Biopharmaceutical company Alumis Inc. on Monday said it plans to offer 17.65 million shares at an estimated price range of $16 to $18 a share in its upcoming initial public offering. At the midpoint o...
Alumis, a biotech focused on immune-mediated diseases, files for a $100 million IPO
Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Alumis IPO Registration Document (S-1)
Alumis has filed to go public with an IPO on the NASDAQ.